Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma of Lung × fludarabine × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 24 Ovarian Neoplasms 13 Melanoma 11 Lung Neoplasms 11 Breast Neoplasms 8 Stomach Neoplasms 7 Pancreatic Neoplasms 7 Colorectal Neoplasms 7 Triple Negative Breast Neoplasms 6 Neoplasms 6 Neoplasm Metastasis 5 Mesothelioma 5 Carcinoma, Merkel Cell 5 Multiple Myeloma 4 Head and Neck Neoplasms 4 Esophageal Neoplasms 4 Carcinoma, Transitional Cell 4 Carcinoma, Renal Cell 4 Carcinoma, Hepatocellular 4 Uterine Cervical Neoplasms 3 Urinary Bladder Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Liver Neoplasms 3 Urogenital Neoplasms 2 Sarcoma, Synovial 2 Recurrence 2 Neuroendocrine Tumors 2 Microsatellite Instability 2 Mesothelioma, Malignant 2

Interventions

Carboplatin 61 Paclitaxel 42 Radiotherapy 39 Cisplatin 37 Pemetrexed 36 Bevacizumab 36 Docetaxel 25 Gemcitabine 24 Erlotinib Hydrochloride 20 Gefitinib 17 pembrolizumab 13 Taxes 10 Cetuximab 10 Magnetic Resonance Spectroscopy 8 Vinorelbine 7 Nivolumab 7 Surgical Procedures, Operative 6 Radiotherapy, Conformal 6 Radiosurgery 6 Radiation 6 Platinum 6 Etoposide 6 capmatinib 5 Specimen Handling 5 Neoadjuvant Therapy 5 Mastectomy, Segmental 5 Cyclophosphamide 5 Biopsy 5 ceritinib 4 aflutinib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05566223 2026-02-23

CheckCell-2

Intima Bioscience, Inc.

Phase 1/2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡